share_log

賽生藥業：截至2024年2月29日之股份發行人的證券變動月報表

SCICLONE PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

香港交易所 ·  Mar 6 04:29
Summary by Moomoo AI
賽生藥業於2024年2月29日提交了最新的證券變動月報表，報告顯示公司法定/註冊股本及已發行股份在2月份均無變動，維持在1,000,000,000股，每股面值0.00005美元，總股本為50,000美元。根據股份期權計劃，賽生藥業在2月份有股份期權變動，其中首次公開發售後購股權計劃下，已行使期權減少128,360股，已失效期權減少50,000股，本月底結存股份期權數目為34,388,230股。本月內因行使期權所得資金總額為1,197,407.52港元。該報告由執行董事、首席財務官兼聯席公司秘書潘蓉容於2024年3月6日呈交。
賽生藥業於2024年2月29日提交了最新的證券變動月報表，報告顯示公司法定/註冊股本及已發行股份在2月份均無變動，維持在1,000,000,000股，每股面值0.00005美元，總股本為50,000美元。根據股份期權計劃，賽生藥業在2月份有股份期權變動，其中首次公開發售後購股權計劃下，已行使期權減少128,360股，已失效期權減少50,000股，本月底結存股份期權數目為34,388,230股。本月內因行使期權所得資金總額為1,197,407.52港元。該報告由執行董事、首席財務官兼聯席公司秘書潘蓉容於2024年3月6日呈交。
SESONG PHARMACEUTICALS FILED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES ON FEBRUARY 29, 2024, SHOWING THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED IN FEBRUARY AT 1,000,000,000 SHARES WITH A NET VALUE OF $0.00005 PER SHARE AND A TOTAL SHARE CAPITAL OF $50,000. Under the share option plan, Saiseng Pharmaceuticals had a share option change in February, in which 128,360 share options were exercised under the Initial Public Offering Option Scheme, and the number of outstanding options was reduced by 50,000 shares, and the number of stock options outstanding at the end of the month was 34,388,230 shares. The total amount of capital gained from the exercise of options during the month was HK$1,197,407.52. The report was submitted by the Executive Director, Chief Financial Officer and Joint Secretary of the Joint Company Pan Rung-yong on 6 March 2024.
SESONG PHARMACEUTICALS FILED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES ON FEBRUARY 29, 2024, SHOWING THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED IN FEBRUARY AT 1,000,000,000 SHARES WITH A NET VALUE OF $0.00005 PER SHARE AND A TOTAL SHARE CAPITAL OF $50,000. Under the share option plan, Saiseng Pharmaceuticals had a share option change in February, in which 128,360 share options were exercised under the Initial Public Offering Option Scheme, and the number of outstanding options was reduced by 50,000 shares, and the number of stock options outstanding at the end of the month was 34,388,230 shares. The total amount of capital gained from the exercise of options during the month was HK$1,197,407.52. The report was submitted by the Executive Director, Chief Financial Officer and Joint Secretary of the Joint Company Pan Rung-yong on 6 March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more